Literature DB >> 1863874

Antisense agents in cancer research and therapeutics.

B J Dolnick1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1863874     DOI: 10.3109/07357909109044229

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  7 in total

1.  Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb.

Authors:  I J Moon; Y Lee; C S Kwak; J H Lee; K Choi; A D Schreiber; J G Park
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

Review 2.  Growth factors in gliomas: antisense and dominant negative mutant strategies.

Authors:  J W Campbell; I F Pollack
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

3.  The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells.

Authors:  F Bost; R McKay; M Bost; O Potapova; N M Dean; D Mercola
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

4.  Quantitative evaluation of intracellular sense: antisense RNA hybrid duplexes.

Authors:  S Wang; B J Dolnick
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

Review 5.  Inhibitors of phosphatidylinositol signalling as antiproliferative agents.

Authors:  G Powis; D Phil
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

6.  Deprotection of methylphosphonate oligonucleotides using a novel one-pot procedure.

Authors:  R I Hogrefe; M M Vaghefi; M A Reynolds; K M Young; L J Arnold
Journal:  Nucleic Acids Res       Date:  1993-05-11       Impact factor: 16.971

Review 7.  Antisense technology for cancer therapy: does it make sense?

Authors:  G Carter; N R Lemoine
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.